Ftse Mib
35.119,39
0,92%
DAX
20.246,95
0,54%
S&P 500
5.834,03
-0,04%
NASDAQ
19.051,57
-0,19%
Bitcoin
95.921,72
1,50%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immutep Ltd (IMMP) Immutep Ltd (IMMP) Notizie

IMMP

Immutep (IMMP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMMP
DataOraFonteTitoloSimboloCompagnia
06/01/202514:00GlobeNewswire Inc.Patient Enrolment Completed for INSIGHT-003NASDAQ:IMMPImmutep Ltd
17/12/202414:00GlobeNewswire Inc.Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761NASDAQ:IMMPImmutep Ltd
16/12/202414:00GlobeNewswire Inc.Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IINASDAQ:IMMPImmutep Ltd
12/12/202421:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
12/12/202414:15GlobeNewswire Inc.Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024NASDAQ:IMMPImmutep Ltd
10/12/202414:00GlobeNewswire Inc.Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
14/11/202414:15GlobeNewswire Inc.Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
14/11/202414:00GlobeNewswire Inc.Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual MeetingNASDAQ:IMMPImmutep Ltd
29/10/202413:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY25NASDAQ:IMMPImmutep Ltd
28/10/202413:00GlobeNewswire Inc.Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024NASDAQ:IMMPImmutep Ltd
17/10/202414:00GlobeNewswire Inc.Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of TrialNASDAQ:IMMPImmutep Ltd
10/10/202414:00GlobeNewswire Inc.Immutep to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:IMMPImmutep Ltd
03/10/202414:00GlobeNewswire Inc.Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
24/09/202414:00GlobeNewswire Inc.Immutep Receives A$3.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
18/09/202414:00GlobeNewswire Inc.New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
16/09/202414:00GlobeNewswire Inc.Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerNASDAQ:IMMPImmutep Ltd
20/08/202414:00GlobeNewswire Inc.Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024NASDAQ:IMMPImmutep Ltd
14/08/202414:00GlobeNewswire Inc.Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 AntibodyNASDAQ:IMMPImmutep Ltd
07/08/202414:00GlobeNewswire Inc.Immutep to Participate in Upcoming Investor ConferencesNASDAQ:IMMPImmutep Ltd
31/07/202414:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY24NASDAQ:IMMPImmutep Ltd
22/07/202414:00GlobeNewswire Inc.Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
17/07/202414:00GlobeNewswire Inc.Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune DiseasesNASDAQ:IMMPImmutep Ltd
12/07/202400:40GlobeNewswire Inc.Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 ExpressionNASDAQ:IMMPImmutep Ltd
03/07/202414:00GlobeNewswire Inc.Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical ResultsNASDAQ:IMMPImmutep Ltd
25/06/202414:00GlobeNewswire Inc.Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for CancerNASDAQ:IMMPImmutep Ltd
05/06/202412:00GlobeNewswire Inc.Immutep successfully completes institutional placement and institutional component of entitlement offerNASDAQ:IMMPImmutep Ltd
03/06/202402:38GlobeNewswire Inc.Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III TrialNASDAQ:IMMPImmutep Ltd
15/05/202414:00GlobeNewswire Inc.Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024NASDAQ:IMMPImmutep Ltd
02/05/202414:00GlobeNewswire Inc.Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
29/04/202414:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q3 FY24NASDAQ:IMMPImmutep Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMMP

La tua Cronologia

TG
LCHI
Amundi MSCI China ESG Le...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network